Indom

Indometacin, the active ingredient in Indom, is a nonsteroidal anti-inflammatory drug presented as an ocular solution for ocular use. It reduces inflammation and pain in the eye, particularly after surgery or in allergic conjunctivitis. GNH USA supplies Indom as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Indometacin ophthalmic is used to manage inflammatory conditions of the eye by inhibiting prostaglandin synthesis. - Post‑operative ocular inflammation: diminishes swelling and discomfort after eye surgery. - Allergic conjunctivitis: relieves redness, itching and swelling caused by allergic reactions. - Anterior uveitis: helps control inflammation of the front part of the eye.

Indometacin ophthalmic may cause local and systemic adverse reactions.

Common Side Effects: - Burning or stinging sensation: transient discomfort upon instillation. - Blurred vision: temporary visual disturbance that resolves. - Redness of the conjunctiva: mild irritation of the eye surface. - Tearing: increased lacrimation after dosing.

Serious or Rare Side Effects: - Corneal ulceration: rare but severe damage to the corneal surface. - Anterior uveitis exacerbation: worsening of intra‑ocular inflammation. - Systemic gastrointestinal ulceration: possible if significant systemic absorption occurs. - Renal impairment: rare renal function changes in susceptible patients.

Indometacin eye drops require careful use to minimise risk. - Hypersensitivity: avoid if patient has known allergy to indometacin or other NSAIDs. - Corneal disease: use with caution in patients with epithelial defects or keratitis. - Pregnancy and lactation: safety not established; consider alternative therapy. - Systemic NSAID use: monitor for additive gastrointestinal or renal effects. - Renal insufficiency: assess renal function before initiating therapy. - Store at room temperature: keep in original container, protect from light and moisture.

Indometacin ophthalmic can interact with systemic and ocular agents.

Major Interactions (Avoid): - Systemic anticoagulants (e.g., warfarin): increased bleeding risk. - Systemic corticosteroids: heightened risk of gastrointestinal ulceration.

Moderate Interactions (Monitor Closely): - Other topical NSAIDs: additive ocular irritation. - Beta‑blocker eye drops: possible reduction in intra‑ocular pressure control. - Diuretics: monitor renal function if systemic absorption is significant.